DMPA, zalcitabine, and the FDA

Lancet. 1992 Jul 4;340(8810):45.
No abstract available

Publication types

  • News

MeSH terms

  • Contraceptive Agents, Female / adverse effects*
  • Contraceptive Agents, Female / therapeutic use
  • Humans
  • Medroxyprogesterone / adverse effects
  • Medroxyprogesterone / analogs & derivatives*
  • Medroxyprogesterone / therapeutic use
  • Medroxyprogesterone Acetate
  • United States
  • United States Food and Drug Administration*
  • Zalcitabine / therapeutic use*

Substances

  • Contraceptive Agents, Female
  • Zalcitabine
  • Medroxyprogesterone Acetate
  • Medroxyprogesterone